Bioventus Inc. (NYSE:BVS) Holdings Trimmed by EntryPoint Capital LLC

EntryPoint Capital LLC cut its holdings in Bioventus Inc. (NYSE:BVS) by 33.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 26,323 shares of the company’s stock after selling 12,979 shares during the quarter. EntryPoint Capital LLC’s holdings in Bioventus were worth $276,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of BVS. Vanguard Group Inc. boosted its stake in shares of Bioventus by 18.7% during the 4th quarter. Vanguard Group Inc. now owns 2,462,081 shares of the company’s stock worth $25,852,000 after acquiring an additional 388,174 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Bioventus by 38.7% in the 4th quarter. American Century Companies Inc. now owns 884,673 shares of the company’s stock valued at $9,289,000 after purchasing an additional 246,645 shares during the period. State Street Corp increased its stake in Bioventus by 38.8% in the 3rd quarter. State Street Corp now owns 676,501 shares of the company’s stock worth $8,084,000 after purchasing an additional 189,216 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Bioventus by 228.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company’s stock worth $3,032,000 after buying an additional 176,442 shares during the period. Finally, FMR LLC lifted its stake in Bioventus by 21,256.6% during the third quarter. FMR LLC now owns 166,795 shares of the company’s stock valued at $1,993,000 after buying an additional 166,014 shares in the last quarter. 62.94% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

BVS has been the topic of several analyst reports. JPMorgan Chase & Co. raised shares of Bioventus from an “underweight” rating to a “neutral” rating and lifted their target price for the stock from $12.00 to $13.00 in a research report on Tuesday, December 17th. Canaccord Genuity Group reiterated a “buy” rating and set a $15.00 price objective on shares of Bioventus in a research report on Monday, March 17th.

Bioventus Trading Down 0.7 %

NYSE:BVS opened at $9.03 on Friday. The stock has a market cap of $739.95 million, a PE ratio of -14.80 and a beta of 0.86. Bioventus Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.38. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The stock’s 50-day moving average is $10.07 and its two-hundred day moving average is $10.97.

Insider Activity at Bioventus

In related news, SVP Anthony D’adamio sold 4,380 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the sale, the senior vice president now directly owns 118,178 shares in the company, valued at approximately $1,204,233.82. This trade represents a 3.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert E. Claypoole sold 28,786 shares of the business’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $9.10, for a total value of $261,952.60. Following the completion of the transaction, the chief executive officer now owns 64,964 shares in the company, valued at $591,172.40. This trade represents a 30.71 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 46,161 shares of company stock valued at $436,364. Corporate insiders own 32.90% of the company’s stock.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.